Hopes raised for early blood test to help fight Alzheimer’s disease

Studies measuring levels of the protein tau in blood offer hope of developing treatments

Scientists say they have made progress towards a test for Alzheimer’s that could help researchers in the hunt for treatments for the disease.

Several studies, presented at a conference in Chicago, showed it was possible to measure the levels of a protein called tau in the blood. Tau and another protein called amyloid have been targets for developing tests and treatments for Alzheimer’s for many years. They form clusters known as tangles and plaques in the brain that are well-known features of the disease.

Any test will help research by identifying people who have the early stages of the disease and may not yet have any symptoms.

Scientists hope it may be possible to develop treatments that work at an early stage, since little seems to slow or halt its progress once it is well established. At present, any early tests for the disease rely on expensive or invasive means, such as brain scans and spinal fluid tests.

“A reliable blood test for Alzheimer’s disease would be a huge boost for dementia research,” said Dr Rosa Sancho, head of research at Alzheimer’s Research UK.

Scientists presenting their research at the Alzheimer’s Association International Conference were targeting a particular form of the tau protein called p-tau217.

One of the studies found that measuring blood p-tau217 could distinguish Alzheimer’s from other neurodegenerative disorders with a diagnostic accuracy between 89% and 98%.

“A cost effective, accurate and non-invasive diagnostic test is a vital step in developing new treatments for the 850,000 people living with dementia in the UK today,” said Fiona Carragher from the Alzheimer’s Society.

Excitingly, this blood test for tau appears to not only show signs of being able to accurately distinguish between Alzheimer’s disease and other neurodegenerative conditions, but also may detect changes before symptoms even appear.

Now we need longer and larger studies to validate these results and find out if this test could accelerate our ability to develop new treatments for Alzheimer’s disease in the future.”

Clive Ballard, professor of age-related disease at the University of Exeter Medical School, said the research was an exciting step forward, but “further validation in people from more routine clinical settings are still needed, and a lot of work will be needed to achieve standardisation of the test across laboratories – so it could still be at least five years before we see an accurate blood biomarker test for dementia in the clinic.”


Sarah Boseley Health editor

The GuardianTramp

Related Content

Article image
Scientists develop blood test for Alzheimer’s disease
Scientists say test could replace a costly brain scan or painful lumbar puncture and enable earlier detection of disease

Linda Geddes Science correspondent

28, Dec, 2022 @12:01 AM

Article image
Long naps may be early sign of Alzheimer’s disease, study shows
Excessive daytime napping likely to be symptom rather than cause of mental decline, say scientists

Hannah Devlin Science corespondent

17, Mar, 2022 @3:37 PM

Article image
Alzheimer’s blood test could predict onset up to 20 years in advance
US researchers say blood test can be 94% effective in spotting those at risk of the disease

Kevin Rawlinson

02, Aug, 2019 @8:18 AM

Article image
Alzheimer’s study finds 42 more genes linked to higher risk of disease
Evidence linking Alzheimer’s to disruption in the brain’s immune system is hailed as ‘enormous clue’

Hannah Devlin Science correspondent

04, Apr, 2022 @3:00 PM

Article image
Blood test could detect Alzheimer's more than 10 years earlier – study
Changes in levels of a protein might reveal onset of disease long before symptoms appear

Nicola Davis

21, Jan, 2019 @4:00 PM

Article image
Study finds link between Alzheimer’s and circadian clock
Research raises hopes for new therapies that could help tackle disease and symptoms

Ian Sample Science editor

10, Feb, 2022 @7:00 PM

Article image
Success of experimental Alzheimer’s drug hailed as ‘historic moment’
Study shows cognition in early-stage patients on lecanemab declines by 27% less than those on placebo

Hannah Devlin Science correspondent

28, Sep, 2022 @1:05 PM

Article image
New Alzheimer's test can predict age when disease will appear
Test based on 31 genetic markers could be used to calculate any individual’s yearly risk for onset of disease

Hannah Devlin

22, Mar, 2017 @6:00 AM

Article image
FDA approves first new Alzheimer’s drug in almost 20 years
Usefulness of aducanumab is disputed but US approval will trigger push to make it available globally

Sarah Boseley

07, Jun, 2021 @3:55 PM

Article image
Blood test could help detect cancer in people with nonspecific symptoms
Study finds test works on people with concerning signs such as unexplained weight loss or fatigue

Linda Geddes

05, Jan, 2022 @12:05 AM